19 November 2017
News and Views
Links and Services
The latest issue of the Alimentary Pharmacology & Therapeutics investigates maintenance of clinical benefit in Crohn’s disease patients after discontinuation of infliximab.
Tumor necrosis factor-blockade with infliximab has advanced the treatment of Crohn’s disease.
Email this page to a colleague
GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors